National Pension Service increased its stake in Boston Scientific Corporation (NYSE:BSX) by 6.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,126,853 shares of the medical equipment provider’s stock after buying an additional 68,186 shares during the period. National Pension Service owned approximately 0.08% of Boston Scientific Corporation worth $31,349,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Quadrant Capital Group LLC increased its position in shares of Boston Scientific Corporation by 10.3% in the first quarter. Quadrant Capital Group LLC now owns 5,201 shares of the medical equipment provider’s stock worth $122,000 after buying an additional 487 shares in the last quarter. Bronfman E.L. Rothschild L.P. increased its position in shares of Boston Scientific Corporation by 7.2% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 5,041 shares of the medical equipment provider’s stock worth $125,000 after buying an additional 338 shares in the last quarter. Guardian Life Insurance Co. of America increased its position in shares of Boston Scientific Corporation by 0.9% in the first quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock worth $131,000 after buying an additional 49 shares in the last quarter. Commerce Bank acquired a new position in shares of Boston Scientific Corporation during the first quarter worth approximately $207,000. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Boston Scientific Corporation during the first quarter worth approximately $215,000. 92.08% of the stock is owned by institutional investors.

Boston Scientific Corporation (BSX) opened at 26.76 on Tuesday. The company has a market capitalization of $36.67 billion, a price-to-earnings ratio of 47.87 and a beta of 1.09. Boston Scientific Corporation has a 52 week low of $19.67 and a 52 week high of $28.51. The firm’s 50-day moving average price is $27.64 and its 200-day moving average price is $25.93.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter in the previous year, the company posted $0.27 EPS. Boston Scientific Corporation’s revenue was up 6.2% on a year-over-year basis. On average, equities analysts expect that Boston Scientific Corporation will post $1.26 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/08/boston-scientific-corporation-nysebsx-shares-bought-by-national-pension-service-updated-updated-updated.html.

A number of research analysts recently commented on the company. UBS AG reissued a “buy” rating and issued a $31.00 price target (up previously from $30.00) on shares of Boston Scientific Corporation in a report on Tuesday, August 1st. BidaskClub downgraded Boston Scientific Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Zacks Investment Research raised Boston Scientific Corporation from a “sell” rating to a “hold” rating in a report on Monday, July 31st. Stifel Nicolaus restated a “buy” rating and set a $32.00 price objective on shares of Boston Scientific Corporation in a research note on Sunday, July 30th. Finally, Oppenheimer Holdings, Inc. set a $29.00 price objective on Boston Scientific Corporation and gave the company a “hold” rating in a research note on Friday, July 28th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $30.06.

In related news, SVP David A. Pierce sold 2,972 shares of the business’s stock in a transaction that occurred on Friday, June 2nd. The shares were sold at an average price of $27.70, for a total value of $82,324.40. Following the completion of the transaction, the senior vice president now owns 28,572 shares in the company, valued at approximately $791,444.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Daniel J. Brennan sold 92,158 shares of the business’s stock in a transaction that occurred on Tuesday, July 11th. The stock was sold at an average price of $27.48, for a total transaction of $2,532,501.84. Following the completion of the transaction, the chief financial officer now owns 235,421 shares of the company’s stock, valued at approximately $6,469,369.08. The disclosure for this sale can be found here. Insiders sold a total of 236,489 shares of company stock valued at $6,440,888 in the last 90 days. 0.74% of the stock is currently owned by corporate insiders.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.